Physician profile
John Gray Norris
NPI 1114952322
$198,251.61
in general payments reported to CMS, 2019-2025
44 companies · $18K in 2025
The $18K reported for 2025 was more than what 91% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $17K · 2021: $35K · 2022: $50K · 2023: $42K · 2024: $9,859 · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $54K · Food and Beverage: $14K · Consulting Fee: $1,522 · Travel and Lodging: $118 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $54,174.51 |
| Food and Beverage | $14,286.28 |
| Consulting Fee | $1,521.63 |
| Travel and Lodging | $117.60 |
| Education | $116.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $96,866.05 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $38,665.05 | 2019-2025 | Dupixent |
| Celgene Corporation | $17,475.96 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $16,744.50 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Genzyme Corporation | $10,815.41 | 2019-2025 | |
| Pfizer INC. | $2,452.19 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,836.22 | 2020-2025 | Hyqvia, Takhzyro, Cuvitru |
| Genentech USA, INC. | $1,833.13 | 2019-2025 | Xolair |
| Sanofi US Services INC. | $1,462.97 | 2025 | |
| Grifols USA, LLC | $1,302.51 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Optinose US, INC. | $1,232.79 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $983.64 | 2019-2025 | |
| Csl Behring | $924.66 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Amgen INC. | $778.96 | 2021-2025 | Tezspire |
| Biocryst US Sales Co., LLC | $678.92 | 2021-2025 | Orladeyo |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Norris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.